[EATG Global HIV News daily digest] Digest #198-2009

[EATG Global HIV News daily digest]

Global HIV News Daily Digest

Copied as fair use  -  Ana  -





Latest Headlines




  Mortality high with non-AIDS cancers in EuroSIDA despite HAART
  Treatment Saturday 14 November 2009
					
  
12th European AIDS Conference, November 11-13, 2009, Cologne, Germany.
  SOURCE:
NATAP




  Twice-daily darunavir/ritonavir to replace double-boosted PIs
  Treatment Saturday 14 November 2009
					
  
12th European AIDS Conference, November 11-13, 2009, Cologne, Germany.
  SOURCE:
NATAP




  Good 4-year HIV response in people over 60, but high cancer and heart disease rates
  Treatment Saturday 14 November 2009
					
  
12th European AIDS Conference, November 11-13, 2009, Cologne, Germany.


  SOURCE:
NATAP




  Multicohort study confirms continuing Hodgkin lymphoma risk with HAART
  Treatment Saturday 14 November 2009
					
  
12th European AIDS Conference, November 11-13, 2009, Cologne, Germany.
  SOURCE:
NATAP




  Study of once-daily boosted darunavir monotherapy as first-line therapy did not succeed
  Treatment Saturday 14 November 2009
					
  
12th European AIDS Conference, November 11-13, 2009, Cologne, Germany.
  SOURCE:
NATAP




  More evidence of low vitamin D in people taking antiretrovirals
  Treatment Saturday 14 November 2009
					
  
12th European AIDS Conference, November 11-13, 2009, Cologne, Germany.
  SOURCE:
NATAP




  High C-reactive protein and abacavir predict heart disease in case-control study
  Treatment Saturday 14 November 2009
					
  
12th European AIDS Conference, November 11-13, 2009, Cologne, Germany.
  SOURCE:
NATAP




  Serosorting or seroguessing?
  MSM Saturday 14 November 2009
					
  
Researchers termed the behaviour of making assumptions about a person’s
HIV status “seroguessing.” This behaviour can place people at risk for
HIV infection.
  SOURCE:
CATIE




  Study in D.C. to test whether HIV treatment can prevent spread
  Prevention Saturday 14 November 2009
					
  
NIH to offer tools to improve patient tracking, follow-up.
  SOURCE:
The Washington Post




  Global Fund extension of HIV prevention programmes for people at high risk for HIV in Russia will save thousands of young lives
  Prevention Saturday 14 November 2009
					
  
International AIDS Society and International Harm Reduction Association
call on Russian government to simultaneously expand access to HIV
prevention programmes for people who inject drugs. 
  SOURCE:
IAS




  Global Fund to provide $24 million of new funding to fight HIV/AIDS in Russia
  Prevention Saturday 14 November 2009
					
  
This will extend by two years a successful HIV prevention program for
highly vulnerable groups such as injecting drug users and sex workers.
  SOURCE:
Global Fund to Fight AIDS, Tuberculosis and Malaria




  New findings on human genome may be useful for developing specific AIDS drugs
  Basic Science Saturday 14 November 2009
					
  
"For the first time we have very precisely defined areas in the human genome where HIV hardly ever integrates." 
  SOURCE:
The Medical News




  HPV therapeutic vaccine works in an early trial
  HIV & STIs Saturday 14 November 2009
					
  
A therapeutic vaccine designed to help the immune system better control
human papillomavirus was nearly 50 percent effective in eliminating
precancerous genital lesions.
  SOURCE:
AIDSmeds.com




  Higher viral loads associated with metabolic syndrome
  Treatment Saturday 14 November 2009
					
  
An effective ARV regimen is “mandatory for both control of HIV disease
progression and for prevention of metabolic syndrome-related
disorders.” 
  SOURCE:
AIDSmeds.com




  Postnatal HIV transmission seen after infant prophylaxis stopped
  Prevention Saturday 14 November 2009
					
  
A large study of infants uninfected with HIV at 14 weeks of age shows
that transmission of the virus through breast milk occurs after
extended antiretroviral prophylaxis is stopped.
  SOURCE:
Medscape Today




  Poor access to treatment quadruples risk for TB in HIV-positive patients in Eastern Europe
  Tuberculosis & Malaria Saturday 14 November 2009
					
  
HIV-positive patients in Eastern Europe have nearly 4 times the risk of
developing tuberculosis (TB) as HIV-infected patients in Western Europe
because of limited access to antiretroviral therapy (ART).
  SOURCE:
Medscape Today


----------------------------------------------------

DISCLAIMER
The articles in this digest represent a diversity of opinions on topics
of interest to the HIV treatment activist community. The EATG is not
responsible for their content. The articles posted in this digest do
not necessarily reflect EATG views or opinions.
FAIR USE NOTICE
The digest may contain copyrighted material which has not always been
specifically authorised by the copyright owner. Such material is made
available for educational purposes to advance the understanding of
scientific, ethical, legal and social issues. It is believed that this
constitutes a 'fair use' of any such copyrighted material. This
material is distributed without profit.


 

Information in this digest was accurately quoted during its compilation.



  





      
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://mail.eatg.org/pipermail/eatg-forum_eatg.org/attachments/20091114/85b48a54/attachment-0001.html>